February 9, 2023 – Orlando, Florida: Marvin Hausman MD, Chief Medical Officer ofLudwig Enterprises, Inc. and creator of the mRNA Inflammatory Index, lectured University of Central Florida graduate and pre-med students on the role of chronic inflammation in the development of diseases and how mRNA biomarkers may be the key to early detection of inflammation and the prevention of chronic illness.
Chronic illnesses account for 70% of the deaths in the United States. There is growing evidence of a link between inflammation and the development of many chronic illnesses such as diabetes, cancer, copd and rheumatoid arthritis. Dr. Hausman developed the mRNA Inflammatory Index, a patent pending technology, which analyzes 48 separate genetic biomarkers of inflammation to assist in disease diagnosis, monitoring and assessment of pre and post treatment effectiveness.
“mRNA is the secret language of the body,” said Dr. Hausman. “This intracellular communication may be a way for us to discover hidden gene patterns related to inflammatory causation of specific diseases, establish diagnoses and show response to treatment.”
Ludwig Enterprise’s unique diagnostic assay combines with AI and deep machine learningtaking a snapshot at one moment in time during a disease process measuring mRNA inflammatory markers. AI and deep machine learning integrate the results and creates a picture. Pre- and post-treatment snapshots allows for an assessment of therapeutic response.
“Discovered hidden inflammatory patterns may open the door to possible nutritional intervention at an early stage,” added Dr. Hausman. “We may be able to provide truly individualized care through counseling, nutritional medicine, and/or dietary supplementation; tailoring nutrition to the genetic makeup of the individual.”
Ludwig Enterprises has created a proprietary andnatural nutritional anti-inflammatory formulation that has the potential to modulate expression of the genes that produce the molecules that cause inflammation. Through this formulation Ludwigplans to help people build up an internal storehouse of these important anti-inflammatory compounds before someone develops a chronic illness. Then, when disease hits, the body can naturally enhance the immune system and neutralize the out-of-control inflammatory process.
About Ludwig Enterprises, Inc.:
Advancements in medical technology have awarded us with cutting-edge genomic tools, unheard-of even a generation ago. These genomic tools have the potential to not only detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. This early detection may allow doctors to take steps to diagnose and manage illness before it progresses and causes serious health problems. Ludwig’sinnovative testing approach is not only practical but also has the potential to save the healthcare industry billions of dollars in costs. With a virtually untapped market and a billion-dollar healthcare industry, Ludwig is poised to significantly impact how we think about disease and live longer healthier lives. More Info: http://www.ludwigent.com
SAFE HARBOR
Forward-looking statements in this release are made under the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.’s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
For Scientific Related Inquiries
Dr. Marvin S. Hausman MD
Chief Science Officer
503-327-4173
[email protected]
For Business Related Inquiries
Luke J. Fannon
484-429-5846
[email protected]
Ludwig Enterprises,Inc.
Anne Blackstone,
786-235-9026
www.ludwigent.com
SOURCE: Ludwig Enterprises, Inc.